The South African government says it could fill the potential gap in the number of doses it will need of the twice-yearly HIV-prevention jab to end Aids by 2043, by getting a group of local pharmaceutical companies to make generic shots from 2027 onwards. There is, however, a hitch. None of the companies that will be involved have a licence from lenacapavir’s inventor, Gilead Sciences, to make the jab.
Related Posts
Epilepsy SA centres boosted by donation of oxygen equipment
- CoreNews Africa
- June 30, 2025
- 0
Local newsNews Epiroc steps in to support Epilepsy SA Gauteng by donating oxygen machines to assist hundreds of residents at its Springs-based centres. Epiroc […]
News24 | ANALYSIS | Africa and the Middle East crisis: better prepared, but not insulated
- CoreNews Africa
- April 13, 2026
- 0
The timing couldn’t be worse for a continent just beginning to recover from two recent global shocks, write Ronak Gopaldas and Menzi Ndhlovu in ISS […]
The Illusion Of Inclusion: Why Title Deeds Fall Short Of Land Restoration
- CoreNews Africa
- April 10, 2026
- 0
The Pan Africanist Congress’s 1959 manifesto unequivocally stated that the land belongs to the African people, stolen through colonialism and apartheid. Fast forward, and […]